Neutralizing Antibody Responses to Antigenically Drifted Influenza A(H3N2) Viruses among Children and Adolescents following 2014-2015 Inactivated and Live Attenuated Influenza Vaccination

scientific article published on 24 August 2016

Neutralizing Antibody Responses to Antigenically Drifted Influenza A(H3N2) Viruses among Children and Adolescents following 2014-2015 Inactivated and Live Attenuated Influenza Vaccination is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1128/CVI.00297-16
P932PMC publication ID5051070
P698PubMed publication ID27558294

P50authorMargaret ChungQ4793511
Richard ZimmermanQ42658961
Mary Patricia NowalkQ63170708
Min Z LevineQ92432969
Brendan FlanneryQ106490202
Michael SusickQ114338937
Kelly Stefano ColeQ114338952
P2093author name stringSarah Spencer
Judith M Martin
Stacie Jefferson
F Liaini Gross
Krissy Moehling
Crystal Ann Archibald
P2860cites workImmune history shapes specificity of pandemic H1N1 influenza antibody responses.Q30352126
Correlates of protection against influenza infection in humans--on the path to a universal vaccine?Q30352879
Hemagglutination inhibiting antibodies and protection against seasonal and pandemic influenza infectionQ30366832
Live attenuated H7N7 influenza vaccine primes for a vigorous antibody response to inactivated H7N7 influenza vaccine.Q30369136
Evaluation of the Safety and Immunogenicity of a Candidate Pandemic Live Attenuated Influenza Vaccine (pLAIV) Against Influenza A(H7N9).Q30382351
Influenza Vaccine Effectiveness Against 2009 Pandemic Influenza A(H1N1) Virus Differed by Vaccine Type During 2013-2014 in the United States.Q30383312
Sensitivity and specificity of serologic assays for detection of human infection with 2009 pandemic H1N1 virus in U.S. populationsQ30401611
Relationship between haemagglutination-inhibiting antibody titres and clinical protection against influenza: development and application of a bayesian random-effects modelQ33538308
Neuraminidase receptor binding variants of human influenza A(H3N2) viruses resulting from substitution of aspartic acid 151 in the catalytic site: a role in virus attachment?Q33990541
Association between antibody titers and protection against influenza virus infection within householdsQ34106198
T-cell-mediated cross-strain protective immunity elicited by prime-boost vaccination with a live attenuated influenza vaccineQ34338986
Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP) -- United States, 2014-15 influenza seasonQ34433508
Potential antigenic explanation for atypical H1N1 infections among middle-aged adults during the 2013-2014 influenza seasonQ34480810
Antibody landscapes after influenza virus infection or vaccination.Q34580640
Live attenuated and inactivated influenza vaccines in childrenQ34974775
Microneutralization assay titres correlate with protection against seasonal influenza H1N1 and H3N2 in children.Q35673054
Identification of Hemagglutinin Residues Responsible for H3N2 Antigenic Drift during the 2014-2015 Influenza SeasonQ35805949
Hemagglutination Inhibition Antibody Titers as a Correlate of Protection Against Seasonal A/H3N2 Influenza DiseaseQ35837747
Global circulation patterns of seasonal influenza viruses vary with antigenic driftQ35844377
Preexisting Immunity, More Than Aging, Influences Influenza Vaccine ResponsesQ36051992
Seasonal Effectiveness of Live Attenuated and Inactivated Influenza VaccineQ36518793
Influence of pre-existing hemagglutination inhibition titers against historical influenza strains on antibody response to inactivated trivalent influenza vaccine in adults 50-80 years of age.Q36977899
Prevention of antigenically drifted influenza by inactivated and live attenuated vaccinesQ37039271
Correlates of Immunity to Influenza as Determined by Challenge of Children with Live, Attenuated Influenza VaccineQ37091608
Immunological assessment of influenza vaccines and immune correlates of protectionQ38105339
2014-2015 Influenza Vaccine Effectiveness in the United States by Vaccine TypeQ38410159
Integrated Sentinel Surveillance Linking Genetic, Antigenic, and Epidemiologic Monitoring of Influenza Vaccine-Virus Relatedness and Effectiveness During the 2013-2014 Influenza SeasonQ38415770
Variable influenza vaccine effectiveness by subtype: a systematic review and meta-analysis of test-negative design studiesQ38803189
Enhanced Genetic Characterization of Influenza A(H3N2) Viruses and Vaccine Effectiveness by Genetic Group, 2014-2015.Q40670577
Influenza activity - United States, 2014-15 season and composition of the 2015-16 influenza vaccineQ40870040
Update: Influenza activity--United States, September 28, 2014-February 21, 2015.Q41289522
Reduced cross-protection against influenza A(H3N2) subgroup 3C.2a and 3C.3a viruses among Finnish healthcare workers vaccinated with 2013/14 seasonal influenza vaccine.Q41486408
Prevention and Control of Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices, United States, 2015-16 Influenza SeasonQ41510283
Early estimates of seasonal influenza vaccine effectiveness - United States, January 2015.Q41543622
Update: influenza activity - United States, September 28- December 6, 2014.Q41672826
Substitutions near the receptor binding site determine major antigenic change during influenza virus evolutionQ42253862
The role of serum haemagglutination-inhibiting antibody in protection against challenge infection with influenza A2 and B virusesQ42790878
Hemagglutination inhibition antibody titers as a correlate of protection for inactivated influenza vaccines in childrenQ43963300
Comparative efficacy of inactivated and live attenuated influenza vaccinesQ44677378
Live attenuated versus inactivated influenza vaccine in infants and young children.Q55043222
Recommended composition of influenza virus vaccines for use in the 2015–2016 northern hemisphere influenza seasonQ56766119
Cross-reactivity of influenza A (H3N2) hemagglutination-inhibition antibodies induced by an inactivated influenza vaccineQ79732077
Weathering the influenza vaccine crisisQ80879334
P433issue10
P921main subjectattenuated vaccineQ1810913
P304page(s)831-839
P577publication date2016-08-24
P1433published inClinical and Vaccine ImmunologyQ5133811
P1476titleNeutralizing Antibody Responses to Antigenically Drifted Influenza A(H3N2) Viruses among Children and Adolescents following 2014-2015 Inactivated and Live Attenuated Influenza Vaccination
P478volume23

Reverse relations

cites work (P2860)
Q49713969An updated influenza A(H3N2) vaccine generates limited antibody responses to previously encountered antigens in children
Q40618185Cell-Mediated Immunity Against Antigenically Drifted Influenza A(H3N2) Viruses in Children During a Vaccine Mismatch Season
Q47548718Change in the efficacy of influenza vaccination after repeated inoculation under antigenic mismatch: A systematic review and meta-analysis
Q50044242Differential gene expression elicited by children in response to the 2015-16 live attenuated versus inactivated influenza vaccine
Q52315590Imprinting of Repeated Influenza A/H3 Exposures on Antibody Quantity and Antibody Quality: Implications on Seasonal Vaccine Strain Selection and Vaccine Performance.
Q95363302Inflammatory Mediator Expression Associated With Antibody Response Induced by Live Attenuated vs Inactivated Influenza Virus Vaccine in Children
Q47559760Measuring Influenza Neutralizing Antibody Responses to A(H3N2) Viruses in Human Sera by Microneutralization Assays Using MDCK-SIAT1 Cells
Q90339280Prior vaccinations improve immunogenicity of inactivated influenza vaccine in young children aged 6 months to 3 years: A cohort study
Q59357667The Effects of Birth Year, Age and Sex on Hemagglutination Inhibition Antibody Responses to Influenza Vaccination
Q64099538Unreliable usage of a single influenza virus IgM antibody assay in influenza-like illness: A retrospective study of the 2016-2018 flu epidemic

Search more.